Advertisement

Symmetric dimethylation of poly-GR correlates with disease duration in C9orf72 FTLD and ALS and reduces poly-GR phase separation and toxicity

  • Lauren M. Gittings
  • Steven Boeynaems
  • Daniel Lightwood
  • Alison Clargo
  • Sarfaraj Topia
  • Lisa Nakayama
  • Claire Troakes
  • David M. A. Mann
  • Aaron D. Gitler
  • Tammaryn Lashley
  • Adrian M. IsaacsEmail author
Open Access
Correspondence

A GGGGCC repeat expansion in C9orf72 is the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Pathologically, patients are characterised by TDP-43 pathology and distinct inclusions containing dipeptide repeat proteins (DPRs) that are produced by repeat associated non-ATG initiated translation of the repeat expansion. This produces five different DPRs: poly-GA, poly-GR poly-PR poly-AP and poly-GP. Poly-GR and poly-PR have been shown to be highly toxic in in vitro and in vivo models, but the mechanisms are not entirely clear [1]. We investigated whether methylation of arginine residues in poly-GR (which is much more abundant than poly-PR) contributes to disease pathogenesis. Three types of arginine methylation can occur, monomethylarginine (MMA), or dimethylarginine in a symmetric (SDMA) or asymmetric (ADMA) confirmation. ADMA is the most prevalent modification with MMA and SDMA occurring at approximately 20–50% that of ADMA [2]. The importance of arginine methylation in FTD and ALS has recently come to light as methylation of arginine residues within the FTD/ALS-linked proteins FUS and hnRNPA2 is an important regulator of their liquid–liquid phase transition [7].

The presence of methylated DPRs has so far been suggested through indirect methods [3, 5, 10]. Therefore, in order to investigate DPR arginine methylation in C9orf72 FTD/ALS we generated and characterised two novel antibodies that detect the two forms of dimethylated poly-GR (Supplementary Fig. 1, online resource). In frontal cortex, they stained cytoplasmic inclusions only in C9orf72 cases and did not label TDP-43 inclusions (Supplementary Figs. 2 and 3, online resource). A comparison to p62 inclusion numbers in the 15 C9orf72 cases available at the Queen Square Brain Bank showed that 48% and 7% of p62 inclusions were positive for ADMA-GR and SDMA-GR respectively. These data show that arginine methylation of poly-GR is a common post-translational modification in C9orf72 patient brain. Interestingly, a rare C9orf72 homozygous case had few SDMA-GR inclusions (Supplementary Fig. 4, online resource), despite a high load of ADMA-GR, abundant DPR protein pathology and severe clinical features [6]. Given the early age of disease onset and short disease duration in the homozygous case, in conjunction with a low SDMA-GR burden, we hypothesised that SDMA-GR may correlate with clinical severity. To investigate this, the number of ADMA-GR and SDMA-GR inclusions were quantified in the frontal cortex of 37 C9orf72 cases (C9orf72-FTLD n = 22, C9orf72-ALS n = 15; details in Supplementary Table 1) and correlated with age at disease onset, age at death, disease duration and post-mortem delay (Supplementary Table 2). This identified a positive correlation between SDMA-GR and disease duration (r = 0.5139, p = 0.0026) (Fig. 1a), and age at death (r = 0.4568, p = 0.0045) (Fig. 1b). The correlations remained significant when normalised to total DPR burden, measured by p62 staining, (Fig. 1c, d) (Supplementary Table 3), ruling out that SDMA-GR levels were simply reflecting total DPR levels. One possible interpretation of our finding that greater numbers of SDMA-GR are correlated with a longer disease duration and later age at death is that SDMA-GR is protective.
Fig. 1

SDMA-GR correlates positively with disease duration and age at death in C9orf72 patients. Individual C9orf72 cases are represented by green squares and the homozygous case as a red square. Positive correlation between the number of SDMA-GR inclusions and a disease duration (r = 0.51, p = 0.0026, n = 32), and b age at death (r = 0.46, p = 0.0045, n = 37). Positive correlation between the percentage of p62 inclusions with SDMA-GR and c disease duration (r = 0.47, p = 0.0061, n = 32) and d age at death (r = 0.55, p = 0.0005, n = 37). Spearman’s rank correlation coefficient performed for all analyses

We therefore investigated the effect of methylation on GR phase separation and toxicity. We generated synthetic (GR)20 peptides with or without ADMA/SDMA-modifications (Fig. 2a). Both ADMA- and SDMA-poly-GR displayed reduced phase separation, as evident from the higher saturation concentration assayed by turbidity measurements (Fig. 2b, c). Imaging showed that while droplets were less abundant for dimethylated poly-GR, they were larger in size (Fig. 2d). As we have previously reported for other basic peptides, such differences in droplet size stem from differences in the interaction strength of the phase separating molecules [4]. Increased interaction strength increases droplet viscosity and surface tension, thereby reducing droplet fusion, leading to smaller droplets. Increased interaction strength will also lower the saturation concentration of phase separation. Hence, both turbidity measurements and droplet imaging point to a decrease in interaction strength between dimethylated poly-GR molecules. We next compared toxicity to primary neuronal cultures and found that dimethylated poly-GR was less toxic than unmethylated poly-GR (Fig. 2e–g), even though uptake of the peptides was similar (Supplementary Fig. 5, online resource). Hence, the same post-translational modifications that reduce poly-GR phase separation also reduces its neuronal toxicity.
Fig. 2

Arginine dimethylation reduces phase separation and neurotoxicity of poly-GR. a Scheme showing methylation of synthetic (GR)20 peptides. b Phase separation of (GR)20 is reduced by SDMA and ADMA modification, as seen by a reduction in the concentration-dependent turbidity increase, quantified in (c). Mean (n = 3) and SEM are shown. Two-way ANOVA. d Pictures showing increased droplet size of dimethylated (GR)20. Concentration 250 µM. e Scheme of the neurotoxicity assay setup. f Quantification of exogenously added (GR)20 toxicity to mouse primary cortical neurons. Mean (n = 4) and SEM are shown. Two-way ANOVA. g Pictures showing loss of neurons in (GR)20-treated cultures (NeuN staining)

A previous report found no correlation of poly-GR with neurodegeneration or clinical phenotypes [8], while two more recent studies showed poly-GR inclusions did correlate with neurodegeneration [9, 10]. As these previous studies did not specifically label SDMA-GR, our findings provide new insights into the relationship of poly-GR inclusions with clinical phenotypes. Future studies are required to investigate why only SDMA-GR is associated with longer disease duration and age at death, and not ADMA-GR, as both forms were able to affect phase separation and toxicity (see Supplementary discussion, online resource for further discussion). In summary, our data show that arginine methylation is a common post-translation modification of poly-GR in C9orf72 patient brain that may influence disease course.

Notes

Supplementary material

401_2019_2104_MOESM1_ESM.pdf (808 kb)
Supplementary file1 (PDF 807 kb)

References

  1. 1.
    Balendra R, Isaacs AM (2018) C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 14:544–558.  https://doi.org/10.1038/s41582-018-0047-2 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bedford MT, Clarke SG (2009) Protein arginine methylation in mammals: who, what, and why. Mol Cell 33:1–13.  https://doi.org/10.1016/j.molcel.2008.12.013 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Boeynaems S, Bogaert E, Michiels E, Gijselinck I, Sieben A, Jovicic A et al (2016) Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci Rep 6:20877.  https://doi.org/10.1038/srep20877 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Boeynaems S, Holehouse AS, Weinhardt V, Kovacs D, Van Lindt J, Larabell C et al (2019) Spontaneous driving forces give rise to protein-RNA condensates with coexisting phases and complex material properties. Proc Natl Acad Sci USA 116:7889–7898.  https://doi.org/10.1073/pnas.1821038116 CrossRefPubMedGoogle Scholar
  5. 5.
    Chitiprolu M, Jagow C, Tremblay V, Bondy-Chorney E, Paris G, Savard A et al (2018) A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy. Nat Commun 9:2794.  https://doi.org/10.1038/s41467-018-05273-7 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fratta P, Poulter M, Lashley T, Rohrer JD, Polke JM, Beck J et al (2013) Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol 126:401–409.  https://doi.org/10.1007/s00401-013-1147-0 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hofweber M, Dormann D (2019) Friend or foe-post-translational modifications as regulators of phase separation and RNP granule dynamics. J Biol Chem 294:7137–7150.  https://doi.org/10.1074/jbc.TM118.001189 CrossRefPubMedGoogle Scholar
  8. 8.
    Mackenzie IR, Frick P, Grasser FA, Gendron TF, Petrucelli L, Cashman NR et al (2015) Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol 130:845–861.  https://doi.org/10.1007/s00401-015-1476-2 CrossRefPubMedGoogle Scholar
  9. 9.
    Saberi S, Stauffer JE, Jiang J, Garcia SD, Taylor AE, Schulte D et al (2018) Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol 135:459–474.  https://doi.org/10.1007/s00401-017-1793-8 CrossRefPubMedGoogle Scholar
  10. 10.
    Sakae N, Bieniek KF, Zhang YJ, Ross K, Gendron TF, Murray ME et al (2018) Poly-GR dipeptide repeat polymers correlate with neurodegeneration and clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol Commun 6:63.  https://doi.org/10.1186/s40478-018-0564-7 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Authors and Affiliations

  • Lauren M. Gittings
    • 1
    • 2
    • 3
  • Steven Boeynaems
    • 4
  • Daniel Lightwood
    • 5
  • Alison Clargo
    • 5
  • Sarfaraj Topia
    • 5
  • Lisa Nakayama
    • 4
  • Claire Troakes
    • 6
  • David M. A. Mann
    • 7
  • Aaron D. Gitler
    • 4
  • Tammaryn Lashley
    • 1
    • 3
  • Adrian M. Isaacs
    • 1
    • 2
    Email author
  1. 1.Department of Neurodegenerative DiseaseUCL Queen Square Institute of NeurologyLondonUK
  2. 2.UK Dementia Research Institute at UCLLondonUK
  3. 3.Queen Square Brain Bank for Neurological DisordersUCL Queen Square Institute of NeurologyLondonUK
  4. 4.Department of GeneticsStanford University School of MedicineStanfordUSA
  5. 5.UCB PharmaSloughUK
  6. 6.London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and NeuroscienceKing’s College LondonLondonUK
  7. 7.Division of Neuroscience and Experimental Psychology, School of Biological SciencesUniversity of Manchester, Salford Royal HospitalSalfordUK

Personalised recommendations